For following the competition: what moved in each program, several studies read as one move.
- inebilizumab
- rilzabrutinib
- Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831
- + 1 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Immunoglobulin G4-Related Disease to watchlistEvery Monday by email · turn it off any timePro · free during the beta